BUZZ-Street View: CVS could meet 2025 growth target despite challenges

Reuters05-03

** Healthcare conglomerate CVS Health on Wednesday sliced its annual adjusted profit forecast by $1.30 to at least $7.00 per share, citing higher medical costs for its Aetna health insurance unit

** CVS says it expects profit per share to grow by low double-digit percent in 2025

POISED FOR GROWTH IN 2025

** Brokerage Jefferies ("buy," PT: $72) sees CVS achieving its 2025 EPS growth target, even though the stock movement reflects "a much more subdued earnings power"

** Jefferies adds that improved U.S. government ratings for Aetna's plans should lead to add $700 mln in adj operating income next year and act as a "building block" for profit growth

** Evercore ISI ("outperform," PT: $65) says CVS's strong commercial insurance wins in public, labor and large national accounts will continue growing into 2025

** Evercore adds that its unit, through which it provides healthcare services in clinics and homes, is poised to improve next year and could see a "step up" in healthcare delivery profit

** Morningstar (PT: $93) says 2025 EPS growth target is above the company's long-term outlook of 6% growth in the intermediate-term, accelerating to 7.5% by 2028

** Barclays ("equal weight," PT: $63) says 2025 EPS target could "elongate" the path to achieve targeted margins of 4%-5% for its Medicare Advantage $(MA)$ business

** Brokerage Stephens says easing competition from CVS in the MA market in 2025 and beyond could benefit rivals UnitedHealth and Humana

(Reporting by Puyaan Singh in Bengaluru)

((Puyaan.Singh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432313959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-03 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432313959","market":"us","top_or_hot":-1,"title":"BUZZ-Street View: CVS could meet 2025 growth target despite challenges","media":"Reuters","content":"<html><body><p>** Healthcare conglomerate CVS Health    on Wednesday sliced its annual adjusted profit forecast by $1.30 to at least $7.00 per share, citing higher medical costs for its Aetna health insurance unit</p><p>   ** CVS says it expects profit per share to grow by low double-digit percent in 2025</p><p>   POISED FOR GROWTH IN 2025</p><p>   ** Brokerage Jefferies (\"buy,\" PT: $72) sees CVS achieving its 2025 EPS growth target, even though the stock movement reflects \"a much more subdued earnings power\" </p><p>   ** Jefferies adds that improved U.S. government ratings for Aetna's plans should lead to add $700 mln in adj operating income next year and act as a \"building block\" for profit growth</p><p>   ** <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI (\"outperform,\" PT: $65) says CVS's strong commercial insurance wins in public, labor and large national accounts will continue growing into 2025 </p><p>       ** Evercore adds that its unit, through which it provides healthcare services in clinics and homes, is poised to improve next year and could see a \"step up\" in healthcare delivery    profit</p><p>   ** Morningstar (PT: $93) says 2025 EPS growth target is above the company's long-term outlook of 6% growth in the intermediate-term, accelerating to 7.5% by 2028</p><p>   ** Barclays (\"equal weight,\" PT: $63) says 2025 EPS target could \"elongate\" the path to achieve targeted margins of 4%-5% for its Medicare Advantage <a href=\"https://laohu8.com/S/MA\">$(MA)$</a> business</p><p>   ** Brokerage Stephens says easing competition from CVS in the MA market in 2025 and beyond could benefit rivals UnitedHealth    and Humana   </p><p> (Reporting by Puyaan Singh in Bengaluru)</p><p>((Puyaan.Singh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: CVS could meet 2025 growth target despite challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: CVS could meet 2025 growth target despite challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 02:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Healthcare conglomerate CVS Health    on Wednesday sliced its annual adjusted profit forecast by $1.30 to at least $7.00 per share, citing higher medical costs for its Aetna health insurance unit  ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0557290698.USD","symbol_name":"施罗德环球可持续增长基金","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2432313959","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432313959","pubTimestamp":1714674648,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Healthcare conglomerate CVS Health    on Wednesday sliced its annual adjusted profit forecast by $1.30 to at least $7.00 per share, citing higher medical costs for its Aetna health insurance unit  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0557290698.USD":"施罗德环球可持续增长基金","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","BK4585":"ETF&股票定投概念","LU0056508442.USD":"贝莱德世界科技基金A2","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","HUM":"哈门那","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0109392836.USD":"富兰克林科技股A","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4527":"明星科技股","BUZZ":"VanEck Social Sentiment ETF","BK4588":"碎股","MA":"万事达","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4154":"管理型保健护理","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","CVS":"西维斯健康","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","UNH":"联合健康","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0276348264.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN\"AUP\" (USD) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BK4581":"高盛持仓","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4504":"桥水持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0289941410.SGD":"AB FCP I Dynamic Diversified AX SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC"},"translate_title":"BUZZ-Street View：尽管面临挑战，CVS仍可实现2025年增长目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MA":1,"BUZZ":1,"CVS":1,"UNH":0.9,"HUM":0.9},"content_text":"** Healthcare conglomerate CVS Health    on Wednesday sliced its annual adjusted profit forecast by $1.30 to at least $7.00 per share, citing higher medical costs for its Aetna health insurance unit   ** CVS says it expects profit per share to grow by low double-digit percent in 2025   POISED FOR GROWTH IN 2025   ** Brokerage Jefferies (\"buy,\" PT: $72) sees CVS achieving its 2025 EPS growth target, even though the stock movement reflects \"a much more subdued earnings power\"    ** Jefferies adds that improved U.S. government ratings for Aetna's plans should lead to add $700 mln in adj operating income next year and act as a \"building block\" for profit growth   ** Evercore ISI (\"outperform,\" PT: $65) says CVS's strong commercial insurance wins in public, labor and large national accounts will continue growing into 2025        ** Evercore adds that its unit, through which it provides healthcare services in clinics and homes, is poised to improve next year and could see a \"step up\" in healthcare delivery    profit   ** Morningstar (PT: $93) says 2025 EPS growth target is above the company's long-term outlook of 6% growth in the intermediate-term, accelerating to 7.5% by 2028   ** Barclays (\"equal weight,\" PT: $63) says 2025 EPS target could \"elongate\" the path to achieve targeted margins of 4%-5% for its Medicare Advantage $(MA)$ business   ** Brokerage Stephens says easing competition from CVS in the MA market in 2025 and beyond could benefit rivals UnitedHealth    and Humana    (Reporting by Puyaan Singh in Bengaluru)((Puyaan.Singh@thomsonreuters.com))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432313959"}